Novartis accelerates efforts toward ESG targets to increase access to medicines, improve health equity and achieve net-zero carbon emissions
September 30, 2021 01:15 ET
|
Novartis Pharma AG
Reached nearly 29 million patients to date in 2021 through our flagship programs and strategic innovative brandsAnnounced a planned 10-year commitment with historically black colleges and universities...
Novartis pledges 10-year commitment with Morehouse School of Medicine, 26 Historically Black Colleges, Universities, Medical Schools and other leading organizations to co-create effective, measurable solutions for health equity
July 20, 2021 07:05 ET
|
Novartis Pharma AG
Novartis and the Novartis US Foundation to join forces with Thurgood Marshall College Fund, Morehouse School of Medicine, 26 other Historically Black Colleges, Universities and Medical Schools and...
Novartis set to achieve 100% renewable electricity in its European operations
November 19, 2020 01:15 ET
|
Novartis International AG
Five virtual power purchase agreements (VPPAs) with three developers expected to add more than 275 megawatts of clean power to the electrical gridProjects expected to address Novartis greenhouse gas...
Novartis reinforces commitment to patient access, pricing a EUR 1.85 billion sustainability-linked bond
September 16, 2020 10:24 ET
|
Novartis International AG
First healthcare industry sustainability-linked bond (SLB) further embeds Environmental Social Governance (ESG) targets into the core of Novartis business operations SLB linked to 2025 Patient Access...
Sandoz announces plans for joint investment to help strengthen future of antibiotics manufacturing in Europe
July 27, 2020 03:29 ET
|
Novartis International AG
Sandoz and Austrian government announce joint plans to drive long-term competitiveness of European production for key antibiotics in Europe Planned combined investment of more than EUR 150 million...
Novartis Resolves Legacy FCPA Investigations
June 25, 2020 13:11 ET
|
Novartis International AG
Basel, June 25, 2020 – Novartis has reached settlements with the US Department of Justice (DOJ) and the US Securities and Exchange Commission (SEC) resolving all Foreign Corrupt Practices Act (FCPA)...
Novartis to sponsor large clinical trial of hydroxychloroquine in hospitalized COVID-19 patients
April 20, 2020 01:32 ET
|
Novartis International AG
Novartis has reached an agreement with the US Food and Drug Administration (FDA) to proceed with a Phase III clinical trial of hydroxychloroquine in hospitalized patients with COVID-19 disease Trial...
Novartis announces plan to initiate clinical study of Jakavi® in severe COVID-19 patients and establish international compassionate use program
April 02, 2020 17:05 ET
|
Novartis International AG
New clinical trial to evaluate Jakavi® (ruxolitinib) in patients with COVID-19 associated cytokine storm Cytokine storm is a type of severe immune overreaction that can result from coronavirus...
Novartis and life sciences companies commit expertise and assets to the fight against COVID-19 pandemic alongside Bill & Melinda Gates Foundation
March 26, 2020 02:15 ET
|
Novartis International AG
Collaboration to address product development and scale up challenges posed by current pandemic Basel, March 26, 2020 — Today, Novartis and a consortium of life sciences companies announced an...
Novartis commits to donate up to 130 million doses of hydroxychloroquine to support the global COVID-19 pandemic response
March 20, 2020 12:00 ET
|
Novartis International AG
Hydroxychloroquine and a related drug, chloroquine, are currently under evaluation in clinical trials for the treatment of COVID-19. Novartis Sandoz division will pursue appropriate regulatory...